Position Statements

7. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes—2018

  1. American Diabetes Association
Diabetes Care 2018 Jan; 41(Supplement 1): S65-S72. https://doi.org/10.2337/dc18-S007

Abstract

The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

There is strong and consistent evidence that obesity management can delay the progression from prediabetes to type 2 diabetes (1,2) and may be beneficial in the treatment of type 2 diabetes (3–8). In overweight and obese patients with type 2 diabetes, modest and sustained weight loss has been shown to improve glycemic control and to reduce the need for glucose-lowering medications (3–5). Small studies have demonstrated that in obese patients with type 2 diabetes more extreme dietary energy restriction with very-low-calorie diets can reduce A1C to <6.5% (48 mmol/mol) and fasting glucose to <126 mg/dL (7.0 mmol/L) in the absence of pharmacologic therapy or ongoing procedures (7,9,10). Weight loss–induced improvements in glycemia are most likely to occur early in the natural history of type 2 diabetes when obesity-associated insulin resistance has caused reversible β-cell dysfunction but insulin secretory capacity remains relatively preserved (5,8,10,11).The goal of this section is to provide evidence-based recommendations for dietary, pharmacologic, and surgical interventions for obesity management as treatments for hyperglycemia in type 2 diabetes.

ASSESSMENT

Recommendation

  • At each patient encounter, BMI should be calculated and documented in the medical record. B

At each routine patient encounter, BMI should be calculated as weight divided by height squared (kg/m2) (12). BMI should be classified to determine the presence of overweight or obesity, discussed with the patient, and documented in the patient record. In Asian Americans, the BMI cutoff points to define overweight and obesity are lower than in other populations (Table 7.1) (13,14). Providers should advise overweight and obese patients that, in general, higher BMIs increase the risk of cardiovascular disease and all-cause mortality. Providers should assess each patient's readiness to achieve weight loss and jointly determine weight loss goals and intervention strategies. Strategies include diet, physical activity, behavioral therapy, pharmacologic therapy, and metabolic surgery (Table 7.1). The latter two strategies may be prescribed for carefully selected patients as adjuncts to diet, physical activity, and behavioral therapy.

View this table:
Table 7.1

Treatment options for overweight and obesity in type 2 diabetes

DIET, PHYSICAL ACTIVITY, AND BEHAVIORAL THERAPY

Recommendations

  • Diet, physical activity, and behavioral therapy designed to achieve >5% weight loss should be prescribed for overweight and obese patients with type 2 diabetes ready to achieve weight loss. A

  • Such interventions should be high intensity (≥16 sessions in 6 months) and focus on diet, physical activity, and behavioral strategies to achieve a 500–750 kcal/day energy deficit. A

  • Diets should be individualized, as those that provide the same caloric restriction but differ in protein, carbohydrate, and fat content are equally effective in achieving weight loss. A

  • For patients who achieve short-term weight-loss goals, long-term (≥1 year) comprehensive weight maintenance programs should be prescribed. Such programs should provide at least monthly contact and encourage ongoing monitoring of body weight (weekly or more frequently), continued consumption of a reduced-calorie diet, and participation in high levels of physical activity (200–300 min/week). A

  • To achieve weight loss of >5%, short-term (3-month) interventions that use very-low-calorie diets (≤800 kcal/day) and total meal replacements may be prescribed for carefully selected patients by trained practitioners in medical care settings with close medical monitoring. To maintain weight loss, such programs must incorporate long-term comprehensive weight maintenance counseling. B

Among overweight or obese patients with type 2 diabetes and inadequate glycemic, blood pressure, and lipid control and/or other obesity-related medical conditions, lifestyle changes that result in modest and sustained weight loss produce clinically meaningful reductions in blood glucose, A1C, and triglycerides (3–5). Greater weight loss produces even greater benefits, including reductions in blood pressure, improvements in LDL and HDL cholesterol, and reductions in the need for medications to control blood glucose, blood pressure, and lipids (3–5).

Look AHEAD Trial

Although the Action for Health in Diabetes (Look AHEAD) trial did not show that an intensive lifestyle intervention reduced cardiovascular events in overweight or obese adults with type 2 diabetes (15), it did show the feasibility of achieving and maintaining long-term weight loss in patients with type 2 diabetes. In the Look AHEAD intensive lifestyle intervention group, mean weight loss was 4.7% at 8 years (16). Approximately 50% of intensive lifestyle intervention participants lost ≥5%, and 27% lost ≥10% of their initial body weight at 8 years (16). Participants randomly assigned to the intensive lifestyle group achieved equivalent risk factor control but required fewer glucose-, blood pressure–, and lipid-lowering medications than those randomly assigned to standard care. Secondary analyses of the Look AHEAD trial and other large cardiovascular outcome studies document other benefits of weight loss in patients with type 2 diabetes, including improvements in mobility, physical and sexual functioning, and health-related quality of life (17). A post hoc analysis of the Look AHEAD study suggests that heterogeneous treatment effects may have been present. Participants who had moderately or poorly controlled diabetes (A1C 6.8% or higher) as well as both those with well-controlled diabetes (A1C less than 6.8%) and good self-reported health were found to have significantly reduced cardiovascular events with intensive lifestyle intervention during follow-up (18).

Lifestyle Interventions

Weight loss can be attained with lifestyle programs that achieve a 500–750 kcal/day energy deficit or provide approximately 1,200–1,500 kcal/day for women and 1,500–1,800 kcal/day for men, adjusted for the individual's baseline body weight. Although benefits may be seen with as little as 5% weight loss (19), sustained weight loss of ≥7% is optimal.

These diets may differ in the types of foods they restrict (such as high-fat or high-carbohydrate foods) but are effective if they create the necessary energy deficit (12,20–22). Use of meal replacement plans prescribed by trained practitioners, with close patient monitoring, can be beneficial. Within the intensive lifestyle intervention group of the Look AHEAD trial, for example, use of a partial meal replacement plan was associated with improvements in diet quality (23). The diet choice should be based on the patient's health status and preferences.

Intensive behavioral lifestyle interventions should include ≥16 sessions in 6 months and focus on diet, physical activity, and behavioral strategies to achieve an ∼500–750 kcal/day energy deficit. Interventions should be provided by trained interventionists in either individual or group sessions (19).

Overweight and obese patients with type 2 diabetes who have lost weight during the 6-month intensive behavioral lifestyle intervention should be enrolled in long-term (≥1 year) comprehensive weight loss maintenance programs that provide at least monthly contact with a trained interventionist and focus on ongoing monitoring of body weight (weekly or more frequently), continued consumption of a reduced-calorie diet, and participation in high levels of physical activity (200–300 min/week [24]). Some commercial and proprietary weight loss programs have shown promising weight loss results (25).

When provided by trained practitioners in medical care settings with close medical monitoring, short-term (3-month) interventions that use very-low-calorie diets (defined as ≤800 kcal/day) and total meal replacements may achieve greater short-term weight loss (10–15%) than intensive behavioral lifestyle interventions that typically achieve 5% weight loss. However, weight regain following the cessation of very-low-calorie diets is greater than following intensive behavioral lifestyle interventions unless a long-term comprehensive weight loss maintenance program is provided (26,27).

PHARMACOTHERAPY

Recommendations

  • When choosing glucose-lowering medications for overweight or obese patients with type 2 diabetes, consider their effect on weight. E

  • Whenever possible, minimize the medications for comorbid conditions that are associated with weight gain. E

  • Weight loss medications may be effective as adjuncts to diet, physical activity, and behavioral counseling for selected patients with type 2 diabetes and BMI ≥27 kg/m2. Potential benefits must be weighed against the potential risks of the medications. A

  • If a patient's response to weight loss medications is <5% weight loss after 3 months or if there are any safety or tolerability issues at any time, the medication should be discontinued and alternative medications or treatment approaches should be considered. A

Antihyperglycemic Therapy

When evaluating pharmacologic treatments for overweight or obese patients with type 2 diabetes, providers should first consider their choice of glucose-lowering medications. Whenever possible, medications should be chosen to promote weight loss or to be weight neutral. Agents associated with weight loss include metformin, α-glucosidase inhibitors, sodium–glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and amylin mimetics. Dipeptidyl peptidase 4 inhibitors appear to be weight neutral. Unlike these agents, insulin secretagogues, thiazolidinediones, and insulin have often been associated with weight gain (see Section 8. Pharmacologic Approaches to Glycemic Treatment”).

A recent meta-analysis of 227 randomized controlled trials of antihyperglycemic treatments in type 2 diabetes found that A1C changes were not associated with baseline BMI, indicating that obese patients can benefit from the same types of treatments for diabetes as normal-weight patients (28).

Concomitant Medications

Providers should carefully review the patient's concomitant medications and, whenever possible, minimize or provide alternatives for medications that promote weight gain. Medications associated with weight gain include atypical antipsychotics (e.g., clozapine, olanzapine, risperidone, etc.) and antidepressants (e.g., tricyclic antidepressants, selective serotonin reuptake inhibitors, and monoamine oxidase inhibitors), glucocorticoids, oral contraceptives that contain progestins, anticonvulsants including gabapentin, and a number of antihistamines and anticholinergics.

Approved Weight Loss Medications

The U.S. Food and Drug Administration (FDA) has approved medications for both short-term and long-term weight management. Phentermine is indicated as short-term (a few weeks) adjunct in conjunction with lifestyle and behavioral weight loss interventions (29). Five weight loss medications (or combination medications) are FDA-approved for long-term use (more than a few weeks) by patients with BMI ≥27 kg/m2 with one or more obesity-associated comorbid conditions (e.g., type 2 diabetes, hypertension, and dyslipidemia) and by patients with BMI ≥30 kg/m2 who are motivated to lose weight (30–34). Medications approved by the FDA for the treatment of obesity and their advantages and disadvantages are summarized in Table 7.2. The rationale for weight loss medications is to help patients to more consistently adhere to low-calorie diets and to reinforce lifestyle changes including physical activity. Providers should be knowledgeable about the product label and should balance the potential benefits of successful weight loss against the potential risks of the medication for each patient. These medications are contraindicated in women who are or may become pregnant. Women in their reproductive years must be cautioned to use a reliable method of contraception.

View this table:
Table 7.2

Medications approved by the FDA for the treatment of obesity

Assessing Efficacy and Safety

Efficacy and safety should be assessed at least monthly for the first 3 months of treatment. If a patient's response is deemed insufficient (weight loss <5%) after 3 months or if there are any safety or tolerability issues at any time, the medication should be discontinued and alternative medications or treatment approaches should be considered.

In general, pharmacologic treatment of obesity has been limited by low adherence, modest efficacy, adverse effects, and weight regain after medication cessation (30).

METABOLIC SURGERY

Recommendations

  • Metabolic surgery should be recommended as an option to treat type 2 diabetes in appropriate surgical candidates with BMI ≥40 kg/m2 (BMI ≥37.5 kg/m2 in Asian Americans), regardless of the level of glycemic control or complexity of glucose-lowering regimens, and in adults with BMI 35.0–39.9 kg/m2 (32.5–37.4 kg/m2 in Asian Americans) when hyperglycemia is inadequately controlled despite lifestyle and optimal medical therapy. A

  • Metabolic surgery should be considered as an option for adults with type 2 diabetes and BMI 30.0–34.9 kg/m2 (27.5–32.4 kg/m2 in Asian Americans) if hyperglycemia is inadequately controlled despite optimal medical control by either oral or injectable medications (including insulin). B

  • Metabolic surgery should be performed in high-volume centers with multidisciplinary teams that understand and are experienced in the management of diabetes and gastrointestinal surgery. C

  • Long-term lifestyle support and routine monitoring of micronutrient and nutritional status must be provided to patients after surgery, according to guidelines for postoperative management of metabolic surgery by national and international professional societies. C

  • People presenting for metabolic surgery should receive a comprehensive mental health assessment. B Surgery should be postponed in patients with histories of alcohol or substance abuse, significant depression, suicidal ideation, or other mental health conditions until these conditions have been fully addressed. E

  • People who undergo metabolic surgery should be evaluated to assess the need for ongoing mental health services to help them adjust to medical and psychosocial changes after surgery. C

Several gastrointestinal (GI) operations including partial gastrectomies and bariatric procedures (35) promote dramatic and durable improvement of type 2 diabetes. Given the magnitude and rapidity of the effect of GI surgery on hyperglycemia, and experimental evidence that rearrangements of GI anatomy similar to those in some metabolic procedures directly affect glucose homeostasis (36), GI interventions have been suggested as treatments for type 2 diabetes, and in that context are termed “metabolic surgery.”

A substantial body of evidence has now accumulated, including data from numerous randomized controlled clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in obese patients with type 2 diabetes compared with various lifestyle/medical interventions (35). Improvements in micro- and macrovascular complications of diabetes, cardiovascular disease, and cancer have been observed only in nonrandomized observational studies (37–46). Cohort studies attempting to match surgical and nonsurgical subjects suggest that the procedure may reduce longer-term mortality (38).

On the basis of this mounting evidence, several organizations and government agencies have recommended expanding the indications for metabolic surgery to include patients with inadequately controlled type 2 diabetes and BMI as low as 30 kg/m2 (27.5 kg/m2 for Asian Americans) (47–50). Please refer to “Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations” for a thorough review (35).

Randomized controlled trials with postoperative follow up ranging from 1 to 5 years have documented sustained diabetes remission in 30–63% of patients (35). Available data suggest an erosion of diabetes remission over time (51): 35–50% or more of patients who initially achieve remission of diabetes eventually experience recurrence. However, the median disease-free period among such individuals following Roux-en-Y gastric bypass (RYGB) is 8.3 years (52,53). With or without diabetes relapse, the majority of patients who undergo surgery maintain substantial improvement of glycemic control from baseline for at least 5 (54,55) to 15 (38,39,53,56–58) years.

Younger age, shorter duration of diabetes (e.g., <8 years) (59), nonuse of insulin, and better glycemic control are consistently associated with higher rates of diabetes remission and/or lower risk of recidivism (38,57,59). Greater baseline visceral fat area may also help to predict better postoperative outcomes, especially among Asian American patients with type 2 diabetes, who typically have more visceral fat compared with Caucasians with diabetes of the same BMI (60).

Beyond improving glycemia, metabolic surgery has been shown to confer additional health benefits in randomized controlled trials, including greater reductions in cardiovascular disease risk factors (35) and enhancements in quality of life (54,59,61).

The safety of metabolic surgery has improved significantly over the past two decades, with continued refinement of minimally invasive approaches (laparoscopic surgery), enhanced training and credentialing, and involvement of multidisciplinary teams. Mortality rates with metabolic operations are typically 0.1–0.5%, similar to cholecystectomy or hysterectomy (62–66). Morbidity has also dramatically declined with laparoscopic approaches. Major complications rates are 2–6%, with minor complications in up to 15% (62–70), comparing favorably with other commonly performed elective operations (66). Empirical data suggest that proficiency of the operating surgeon is an important factor for determining mortality, complications, reoperations, and readmissions (71).

Although metabolic surgery has been shown to improve the metabolic profiles of morbidly obese patients with type 1 diabetes, establishing the role of metabolic surgery in such patients will require larger and longer studies (72).

Retrospective analyses and modeling studies suggest that metabolic surgery may be cost-effective or even cost-saving for patients with type 2 diabetes, but the results are largely dependent on assumptions about the long-term effectiveness and safety of the procedures (73,74).

Adverse Effects

Metabolic surgery is costly and has associated risks. Longer-term concerns include dumping syndrome (nausea, colic, diarrhea), vitamin and mineral deficiencies, anemia, osteoporosis, and, rarely (75), severe hypoglycemia from insulin hypersecretion. Long-term nutritional and micronutrient deficiencies and related complications occur with variable frequency depending on the type of procedure and require lifelong vitamin/nutritional supplementation (76,77). Postprandial hypoglycemia is most likely to occur with RYGB (77,78). The exact prevalence of symptomatic hypoglycemia is unknown. In one study, it affected 11% of 450 patients who had undergone RYGB or vertical sleeve gastrectomy (75). Patients who undergo metabolic surgery may be at increased risk for substance use, including drug and alcohol use and cigarette smoking (79).

People with diabetes presenting for metabolic surgery also have increased rates of depression and other major psychiatric disorders (80). Candidates for metabolic surgery with histories of alcohol or substance abuse, significant depression, suicidal ideation, or other mental health conditions should therefore first be assessed by a mental health professional with expertise in obesity management prior to consideration for surgery (81). Individuals with preoperative psychopathology should be assessed regularly following metabolic surgery to optimize mental health management and to ensure psychiatric symptoms do not interfere with weight loss and lifestyle changes.

Footnotes

  • Suggested citation: American Diabetes Association. 7. Obesity management for the treatment of type 2 diabetes: Standards of Medical Care in Diabetes—2018. Diabetes Care 2018;41(Suppl. 1):S65–S72

http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

References

  1. ↵
    1. Tuomilehto J
    . The emerging global epidemic of type 1 diabetes. Curr Diab Rep 2013;13:795–804
    OpenUrlCrossRefPubMed
  2. ↵
    1. Knowler WC,
    2. Barrett-Connor E,
    3. Fowler SE, et al.; Diabetes Prevention Program Research Group
    . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. UK Prospective Diabetes Study 7
    . UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS Group. Metabolism 1990;39:905–912
    OpenUrlCrossRefPubMedWeb of Science
    1. Goldstein DJ
    . Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992;16:397–415
    OpenUrlPubMedWeb of Science
  5. ↵
    1. Pastors JG,
    2. Warshaw H,
    3. Daly A,
    4. Franz M,
    5. Kulkarni K
    . The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care 2002;25:608–613
    OpenUrlFREE Full Text
    1. Lim EL,
    2. Hollingsworth KG,
    3. Aribisala BS,
    4. Chen MJ,
    5. Mathers JC,
    6. Taylor R
    . Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011;54:2506–2514
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Jackness C,
    2. Karmally W,
    3. Febres G, et al
    . Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and β-cell function in type 2 diabetic patients. Diabetes 2013;62:3027–3032
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Rothberg AE,
    2. McEwen LN,
    3. Kraftson AT,
    4. Fowler CE,
    5. Herman WH
    . Very-low-energy diet for type 2 diabetes: an underutilized therapy? J Diabetes Complications 2014;28:506–510
    OpenUrlCrossRefPubMed
  9. ↵
    1. Day JW,
    2. Ottaway N,
    3. Patterson JT, et al
    . A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 2009;5:749–757
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Steven S,
    2. Hollingsworth KG,
    3. Al-Mrabeh A, et al
    . Very low-calorie diet and 6 months of weight stability in type 2 diabetes: pathophysiological changes in responders and nonresponders. Diabetes Care 2016;39:808–815
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Schauer PR,
    2. Mingrone G,
    3. Ikramuddin S,
    4. Wolfe B
    . Clinical outcomes of metabolic surgery: efficacy of glycemic control, weight loss, and remission of diabetes. Diabetes Care 2016;39:902–911
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Jensen MD,
    2. Ryan DH,
    3. Apovian CM, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society
    . 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 2014;63(25 Pt B):2985–3023
    OpenUrlFREE Full Text
  13. ↵
    1. Expert Consultation WHO; WHO Expert Consultation
    . Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157–163
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Araneta MR,
    2. Grandinetti A,
    3. Chang HK
    . Optimum BMI cut points to screen Asian Americans for type 2 diabetes: the UCSD Filipino Health Study and the North Kohala Study (Abstract). Diabetes 2014;63(Suppl. 1):A20
    OpenUrl
  15. ↵
    1. Wing RR,
    2. Bolin P,
    3. Brancati FL, et al.; Look AHEAD Research Group
    . Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369:145–154
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Look AHEAD Research Group
    . Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study. Obesity (Silver Spring) 2014;22:5–13
    OpenUrlCrossRefPubMed
  17. ↵
    1. Wilding JPH
    . The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract 2014;68:682–691
    OpenUrlCrossRefPubMed
  18. ↵
    1. Baum A,
    2. Scarpa J,
    3. Bruzelius E,
    4. Tamler R,
    5. Basu S,
    6. Faghmous J
    . Targeting weight loss interventions to reduce cardiovascular complications of type 2 diabetes: a machine learning-based post-hoc analysis of heterogeneous treatment effects in the Look AHEAD trial. Lancet Diabetes Endocrinol 2017;5:808–815
    OpenUrl
  19. ↵
    1. Franz MJ,
    2. Boucher JL,
    3. Rutten-Ramos S,
    4. VanWormer JJ
    . Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J Acad Nutr Diet 2015;115:1447–1463
    OpenUrlCrossRefPubMed
  20. ↵
    1. Sacks FM,
    2. Bray GA,
    3. Carey VJ, et al
    . Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009;360:859–873
    OpenUrlCrossRefPubMedWeb of Science
    1. de Souza RJ,
    2. Bray GA,
    3. Carey VJ, et al
    . Effects of 4 weight-loss diets differing in fat, protein, and carbohydrate on fat mass, lean mass, visceral adipose tissue, and hepatic fat: results from the POUNDS LOST trial. Am J Clin Nutr 2012;95:614–625
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Johnston BC,
    2. Kanters S,
    3. Bandayrel K, et al
    . Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA 2014;312:923–933
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Raynor HA,
    2. Anderson AM,
    3. Miller GD, et al.; Look AHEAD Research Group
    . Partial meal replacement plan and quality of the diet at 1 year: Action for Health in Diabetes (Look AHEAD) trial. J Acad Nutr Diet 2015;115:731–742
    OpenUrl
  24. ↵
    1. Donnelly JE,
    2. Blair SN,
    3. Jakicic JM,
    4. Manore MM,
    5. Rankin JW,
    6. Smith BK; American College of Sports Medicine
    . American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc 2009;41:459–471
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Gudzune KA,
    2. Doshi RS,
    3. Mehta AK, et al
    . Efficacy of commercial weight-loss programs: an updated systematic review. Ann Intern Med 2015;162:501–512
    OpenUrlCrossRefPubMed
  26. ↵
    1. Tsai AG,
    2. Wadden TA
    . The evolution of very-low-calorie diets: an update and meta-analysis. Obesity (Silver Spring) 2006;14:1283–1293
    OpenUrlCrossRefPubMed
  27. ↵
    1. Johansson K,
    2. Neovius M,
    3. Hemmingsson E
    . Effects of anti-obesity drugs, diet, and exercise on weight-loss maintenance after a very-low-calorie diet or low-calorie diet: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 2014;99:14–23
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Cai X,
    2. Yang W,
    3. Gao X,
    4. Zhou L,
    5. Han X,
    6. Ji L
    . Baseline body mass index and the efficacy of hypoglycemic treatment in type 2 diabetes: a meta-analysis. PLoS One 2016;11:e0166625
    OpenUrl
  29. ↵
    1. Phentermine
    . FDA prescribing information, side effects and uses [Internet], 2017. Available from https://www.drugs.com/pro/phentermine.html. Accessed 22 September 2017
  30. ↵
    1. Yanovski SZ,
    2. Yanovski JA
    . Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014;311:74–86
    OpenUrlCrossRefPubMedWeb of Science
    1. Greenway FL,
    2. Fujioka K,
    3. Plodkowski RA, et al.; COR-I Study Group
    . Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376:595–605
    OpenUrlCrossRefPubMedWeb of Science
    1. Pi-Sunyer X,
    2. Astrup A,
    3. Fujioka K, et al.; SCALE Obesity and Prediabetes NN8022-1839 Study Group
    . A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11–22
    OpenUrlCrossRefPubMed
    1. Khera R,
    2. Murad MH,
    3. Chandar AK, et al
    . Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 2016;315:2424–2434
    OpenUrlPubMed
  34. ↵
    1. O’Neil PM,
    2. Smith SR,
    3. Weissman NJ, et al
    . Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 2012;20:1426–1436
    OpenUrlCrossRefPubMed
  35. ↵
    1. Rubino F,
    2. Nathan DM,
    3. Eckel RH, et al.; Delegates of the 2nd Diabetes Surgery Summit
    . Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 2016;39:861–877
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Rubino F,
    2. Marescaux J
    . Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 2004;239:1–11
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    1. Sjöström L,
    2. Lindroos A-K,
    3. Peltonen M, et al.; Swedish Obese Subjects Study Scientific Group
    . Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683–2693
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    1. Sjöström L,
    2. Peltonen M,
    3. Jacobson P, et al
    . Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014;311:2297–2304
    OpenUrlCrossRefPubMedWeb of Science
  39. ↵
    1. Adams TD,
    2. Davidson LE,
    3. Litwin SE, et al
    . Health benefits of gastric bypass surgery after 6 years. JAMA 2012;308:1122–1131
    OpenUrlCrossRefPubMedWeb of Science
    1. Sjöström L,
    2. Narbro K,
    3. Sjöström CD, et al.; Swedish Obese Subjects Study
    . Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007;357:741–752
    OpenUrlCrossRefPubMedWeb of Science
    1. Sjöström L,
    2. Gummesson A,
    3. Sjöström CD, et al.; Swedish Obese Subjects Study
    . Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol 2009;10:653–662
    OpenUrlCrossRefPubMedWeb of Science
    1. Sjöström L,
    2. Peltonen M,
    3. Jacobson P, et al
    . Bariatric surgery and long-term cardiovascular events. JAMA 2012;307:56–65
    OpenUrlCrossRefPubMedWeb of Science
    1. Adams TD,
    2. Gress RE,
    3. Smith SC, et al
    . Long-term mortality after gastric bypass surgery. N Engl J Med 2007;357:753–761
    OpenUrlCrossRefPubMedWeb of Science
    1. Arterburn DE,
    2. Olsen MK,
    3. Smith VA, et al
    . Association between bariatric surgery and long-term survival. JAMA 2015;313:62–70
    OpenUrlCrossRefPubMed
    1. Adams TD,
    2. Arterburn DE,
    3. Nathan DM,
    4. Eckel RH
    . Clinical outcomes of metabolic surgery: microvascular and macrovascular complications. Diabetes Care 2016;39:912–923
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Sheng B,
    2. Truong K,
    3. Spitler H,
    4. Zhang L,
    5. Tong X,
    6. Chen L
    . The long-term effects of bariatric surgery on type 2 diabetes remission, microvascular and macrovascular complications, and mortality: a systematic review and meta-analysis. Obes Surg. 11 August 2017 [Epub ahead of print]. DOI: 10.1007/s11695-017-2866-4
  47. ↵
    1. Rubino F,
    2. Kaplan LM,
    3. Schauer PR,
    4. Cummings DE; Diabetes Surgery Summit Delegates
    . The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg 2010;251:399–405
    OpenUrlCrossRefPubMedWeb of Science
    1. Cummings DE,
    2. Cohen RV
    . Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery. Lancet Diabetes Endocrinol 2014;2:175–181
    OpenUrl
    1. Zimmet P,
    2. Alberti KGMM,
    3. Rubino F,
    4. Dixon JB
    . IDF’s view of bariatric surgery in type 2 diabetes. Lancet 2011;378:108–110
    OpenUrlCrossRefPubMedWeb of Science
  50. ↵
    1. Kasama K,
    2. Mui W,
    3. Lee WJ, et al
    . IFSO-APC consensus statements 2011. Obes Surg 2012;22:677–684
    OpenUrlCrossRefPubMed
  51. ↵
    1. Ikramuddin S,
    2. Korner J,
    3. Lee W-J, et al
    . Durability of addition of Roux-en-Y gastric bypass to lifestyle intervention and medical management in achieving primary treatment goals for uncontrolled type 2 diabetes in mild to moderate obesity: a randomized control trial. Diabetes Care 2016;39:1510–1518
    OpenUrlAbstract/FREE Full Text
  52. ↵
    1. Sjöholm K,
    2. Pajunen P,
    3. Jacobson P, et al
    . Incidence and remission of type 2 diabetes in relation to degree of obesity at baseline and 2 year weight change: the Swedish Obese Subjects (SOS) study. Diabetologia 2015;58:1448–1453
    OpenUrlCrossRefPubMed
  53. ↵
    1. Arterburn DE,
    2. Bogart A,
    3. Sherwood NE, et al
    . A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 2013;23:93–102
    OpenUrlCrossRefPubMed
  54. ↵
    1. Mingrone G,
    2. Panunzi S,
    3. De Gaetano A, et al
    . Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 2015;386:964–973
    OpenUrlCrossRefPubMed
  55. ↵
    1. Schauer PR,
    2. Bhatt DL,
    3. Kirwan JP, et al.; STAMPEDE Investigators
    . Bariatric surgery versus intensive medical therapy for diabetes: 5-year outcomes. N Engl J Med 2017;376:641–651
    OpenUrlPubMed
  56. ↵
    1. Cohen RV,
    2. Pinheiro JC,
    3. Schiavon CA,
    4. Salles JE,
    5. Wajchenberg BL,
    6. Cummings DE
    . Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care 2012;35:1420–1428
    OpenUrlAbstract/FREE Full Text
  57. ↵
    1. Brethauer SA,
    2. Aminian A,
    3. Romero-Talamás H, et al
    . Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus [discussion appears in Ann Surg 2013;258:636–637]. Ann Surg 2013;258:628–636
    OpenUrlPubMed
  58. ↵
    1. Hsu C-C,
    2. Almulaifi A,
    3. Chen J-C, et al
    . Effect of bariatric surgery vs medical treatment on type 2 diabetes in patients with body mass index lower than 35: five-year outcomes. JAMA Surg 2015;150:1117–1124
    OpenUrl
  59. ↵
    1. Schauer PR,
    2. Bhatt DL,
    3. Kirwan JP, et al.; STAMPEDE Investigators
    . Bariatric surgery versus intensive medical therapy for diabetes: 3-year outcomes. N Engl J Med 2014;370:2002–2013
    OpenUrlCrossRefPubMedWeb of Science
  60. ↵
    1. Yu H,
    2. Di J,
    3. Bao Y, et al
    . Visceral fat area as a new predictor of short-term diabetes remission after Roux-en-Y gastric bypass surgery in Chinese patients with a body mass index less than 35 kg/m2. Surg Obes Relat Dis 2015;11:6–11
    OpenUrlCrossRefPubMed
  61. ↵
    1. Halperin F,
    2. Ding S-A,
    3. Simonson DC, et al
    . Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial. JAMA Surg 2014;149:716–726
    OpenUrl
  62. ↵
    1. Flum DR,
    2. Belle SH,
    3. King WC, et al.; Longitudinal Assessment of Bariatric Surgery (LABS) Consortium
    . Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009;361:445–454
    OpenUrlCrossRefPubMedWeb of Science
    1. Courcoulas AP,
    2. Christian NJ,
    3. Belle SH, et al.; Longitudinal Assessment of Bariatric Surgery (LABS) Consortium
    . Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA 2013;310:2416–2425
    OpenUrlPubMedWeb of Science
    1. Arterburn DE,
    2. Courcoulas AP
    . Bariatric surgery for obesity and metabolic conditions in adults. BMJ 2014;349:g3961
    OpenUrlAbstract/FREE Full Text
    1. Young MT,
    2. Gebhart A,
    3. Phelan MJ,
    4. Nguyen NT
    . Use and outcomes of laparoscopic sleeve gastrectomy vs laparoscopic gastric bypass: analysis of the American College of Surgeons NSQIP. J Am Coll Surg 2015;220:880–885
    OpenUrlCrossRefPubMed
  66. ↵
    1. Aminian A,
    2. Brethauer SA,
    3. Kirwan JP,
    4. Kashyap SR,
    5. Burguera B,
    6. Schauer PR
    . How safe is metabolic/diabetes surgery? Diabetes Obes Metab 2015;17:198–201
    OpenUrlCrossRefPubMed
    1. Birkmeyer NJO,
    2. Dimick JB,
    3. Share D, et al.; Michigan Bariatric Surgery Collaborative
    . Hospital complication rates with bariatric surgery in Michigan. JAMA 2010;304:435–442
    OpenUrlCrossRefPubMedWeb of Science
    1. Altieri MS,
    2. Yang J,
    3. Telem DA, et al
    . Lap band outcomes from 19,221 patients across centers and over a decade within the state of New York. Surg Endosc 2016;30:1725–1732
    OpenUrl
    1. Hutter MM,
    2. Schirmer BD,
    3. Jones DB, et al
    . First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass [discussion appears in Ann Surg 2011;254:420–422]. Ann Surg 2011;254:410–420
    OpenUrlCrossRefPubMed
  70. ↵
    1. Nguyen NT,
    2. Slone JA,
    3. Nguyen X-MT,
    4. Hartman JS,
    5. Hoyt DB
    . A prospective randomized trial of laparoscopic gastric bypass versus laparoscopic adjustable gastric banding for the treatment of morbid obesity: outcomes, quality of life, and costs. Ann Surg 2009;250:631–641
    OpenUrlPubMedWeb of Science
  71. ↵
    1. Birkmeyer JD,
    2. Finks JF,
    3. O’Reilly A, et al.; Michigan Bariatric Surgery Collaborative
    . Surgical skill and complication rates after bariatric surgery. N Engl J Med 2013;369:1434–1442
    OpenUrlCrossRefPubMedWeb of Science
  72. ↵
    1. Kirwan JP,
    2. Aminian A,
    3. Kashyap SR,
    4. Burguera B,
    5. Brethauer SA,
    6. Schauer PR
    . Bariatric surgery in obese patients with type 1 diabetes. Diabetes Care 2016;39:941–948
    OpenUrlAbstract/FREE Full Text
  73. ↵
    1. Rubin JK,
    2. Hinrichs-Krapels S,
    3. Hesketh R,
    4. Martin A,
    5. Herman WH,
    6. Rubino F
    . Identifying barriers to appropriate use of metabolic/bariatric surgery for type 2 diabetes treatment: policy lab results. Diabetes Care 2016;39:954–963
    OpenUrlAbstract/FREE Full Text
  74. ↵
    1. Fouse T,
    2. Schauer P
    . The socioeconomic impact of morbid obesity and factors affecting access to obesity surgery. Surg Clin North Am 2016;96:669–679
    OpenUrl
  75. ↵
    1. Service GJ,
    2. Thompson GB,
    3. Service FJ,
    4. Andrews JC,
    5. Collazo-Clavell ML,
    6. Lloyd RV
    . Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005;353:249–254
    OpenUrlCrossRefPubMedWeb of Science
  76. ↵
    1. Mechanick JI,
    2. Kushner RF,
    3. Sugerman HJ, et al.; American Association of Clinical Endocrinologists; Obesity Society; American Society for Metabolic & Bariatric Surgery
    . American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Obesity (Silver Spring) 2009;17(Suppl. 1):S1–S70, v
    OpenUrlPubMed
  77. ↵
    1. Mechanick JI,
    2. Youdim A,
    3. Jones DB, et al.; American Association of Clinical Endocrinologists; Obesity Society; American Society for Metabolic & Bariatric Surgery
    . Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity (Silver Spring) 2013;21(Suppl. 1):S1–S27
    OpenUrlCrossRefPubMed
  78. ↵
    1. Lee CJ,
    2. Clark JM,
    3. Schweitzer M, et al
    . Prevalence of and risk factors for hypoglycemic symptoms after gastric bypass and sleeve gastrectomy. Obesity (Silver Spring) 2015;23:1079–1084
    OpenUrlCrossRefPubMed
  79. ↵
    1. Conason A,
    2. Teixeira J,
    3. Hsu C-H,
    4. Puma L,
    5. Knafo D,
    6. Geliebter A
    . Substance use following bariatric weight loss surgery. JAMA Surg 2013;148:145–150
    OpenUrl
  80. ↵
    1. Young-Hyman D,
    2. Peyrot M
    . Psychosocial Care for People with Diabetes. 1st ed. Virginia, American Diabetes Association, 2012, p. 240
  81. ↵
    1. Greenberg I,
    2. Sogg S,
    3. M Perna F
    . Behavioral and psychological care in weight loss surgery: best practice update. Obesity (Silver Spring) 2009;17:880–884
    OpenUrlCrossRefPubMed
Back to top
View Selected Citations (0)
Print
Download PDF
Article Alerts
Email Article
Citation Tools
Add to Selected Citations

7. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association
Diabetes Care Jan 2018, 41 (Supplement 1) S65-S72; DOI: 10.2337/dc18-S007
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section